Biomarker Research

Article	Citations
Roles of IFN-γ in tumor progression and regression: a review	502
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors	255
Metabolic reprogramming in macrophage responses	207
Biomarkers for cancer-associated fibroblasts	138
Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives	115
A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19)	106
miR-21: a non‐specific biomarker of all maladies	103
Recent advances in systemic therapy for hepatocellular carcinoma	91
The landscape of bispecific T cell engager in cancer treatment	85
Targeting ferroptosis in breast cancer	84
Advances in RNA cytosine-5 methylation: detection, regulatory mechanisms, biological functions and links to cancer	69
CAR-NK cells for cancer immunotherapy: from bench to bedside	64
Epidemiological trends of women’s cancers from 1990 to 2019 at the global, regional, and national levels: a population-based study	63
A comprehensive comparison between camelid nanobodies and single chain variable fragments	62
Trends and projections of kidney cancer incidence at the global and national levels, 1990–2030: a Bayesian age-period-cohort modeling study	61
Novel insights on targeting ferroptosis in cancer therapy	60
Next frontier in tumor immunotherapy: macrophage-mediated immune evasion	59
Role of platelet biomarkers in inflammatory response	58
Biological roles of RNA m5C modification and its implications in Cancer immunotherapy	55
Imaging biomarkers for evaluating tumor response: RECIST and beyond	52
Immunotherapy in endometrial cancer: rationale, practice and perspectives	50
Blood biomarkers for mild traumatic brain injury: a selective review of unresolved issues	48
Alternative Polyadenylation: a new frontier in post transcriptional regulation	48
Nanobody-based CAR-T cells for cancer immunotherapy	48
Role of DNA repair defects in predicting immunotherapy response	47

Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies	47
Anti-Mesothelin CAR T cell therapy for malignant mesothelioma	46
The biological function and clinical significance of SF3B1 mutations in cancer	45
The role of estrogen receptor beta in breast cancer	44
Prolonged elevation of serum neurofilament light after concussion in male Australian football players	44
Temporal trend of gastric cancer burden along with its risk factors in China from 1990 to 2019, and projections until 2030: comparison with Japan, South Korea, and Mongolia	43
Cancer-associated adipocytes as immunomodulators in cancer	43
Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy	42
Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth	42
Single-cell map of diverse immune phenotypes in the acute myeloid leukemia microenvironment	40
Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy	40
Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis	39
The role of ferroptosis in lung cancer	39
Immune cells-derived exosomes function as a double-edged sword: role in disease progression and their therapeutic applications	38
Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients	37
Advances in targeted therapy for acute myeloid leukemia	37
Structures and biological functions of zinc finger proteins and their roles in hepatocellular carcinoma	35
Targeting interleukin-1β and inflammation in lung cancer	35
Detection of circulating tumor cells: opportunities and challenges	34
Risk factors for immune-related adverse events: what have we learned and what lies ahead?	34
TOX as a potential target for immunotherapy in lymphocytic malignancies	33
Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia	32
Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment	32
Application of pharmacogenetics in oncology	32
Bidirectional interaction between intestinal microbiome and cancer: opportunities for therapeutic interventions	31
Dysregulated bile acid receptor-mediated signaling and IL-17A induction are implicated in diet-associated hepatic health and cognitive function	31
The emerging roles of N6-methyladenosine RNA methylation in human cancers	30
Current views on the genetic landscape and management of variant acute promyelocytic leukemia	30
The role of phosphatidylserine on the membrane in immunity and blood coagulation	30
p63 expression in human tumors and normal tissues: a tissue microarray study on 10,200 tumors	30
E-Cadherin expression in human tumors: a tissue microarray study on 10,851 tumors	29
Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed	29
A radiomics-based model on non-contrast CT for predicting cirrhosis: make the most of image data	28
The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer	28
The role of biomarkers in personalized immunotherapy	27
Clinical translation of patient-derived tumour organoids- bottlenecks and strategies	26
Targeting neoantigens for cancer immunotherapy	26
N6-methyladenine modification in noncoding RNAs and its function in cancer	25
The Wnt signaling pathway in tumorigenesis, pharmacological targets, and drug development for cancer therapy	25
EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives	25
Intratumor microbiome in cancer progression: current developments, challenges and future trends	25
Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer	24
Mechanisms of tRNA-derived fragments and tRNA halves in cancer treatment resistance	23
Consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: who? When? Why?	23
Metastasis-associated fibroblasts: an emerging target for metastatic cancer	23
Recent updates on Sintilimab in solid tumor immunotherapy	23
LncRNA SNHG16 as a potential biomarker and therapeutic target in human cancers	23
The emerging landscape of circular RNAs in immunity: breakthroughs and challenges	22
Biomarkers in individualized management of chimeric antigen receptor T cell therapy	22
LncRNA APCDD1L-AS1 induces icotinib resistance by inhibition of EGFR autophagic degradation via the miR-1322/miR-1972/miR-324-3p-SIRT5 axis in lung adenocarcinoma	22

Plasma circulating tumor DNA assessment reveals KMT2D as a potential poor prognostic factor in extranodal NK/T-cell lymphoma	22
Novel insights into the m6A-RNA methyltransferase METTL3 in cancer	22
Advances in the DNA methylation hydroxylase TET1	21
AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report	21
The emerging role of RNA N6-methyladenosine methylation in breast cancer	21
Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma	21
Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy	21
Roles of HMGB1 in regulating myeloid-derived suppressor cells in the tumor microenvironment	20
Characterization of novel dual tandem CD19/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma	20
The significant role of redox system in myeloid leukemia: from pathogenesis to therapeutic applications	20
Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma	20
Advances of cancer-associated fibroblasts in liver cancer	20
Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse	19
Nucleases as molecular targets for cancer diagnosis	18
The intriguing roles of Siglec family members in the tumor microenvironment	18
CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia	18
Novel strategies for immuno-oncology breakthroughs with cell therapy	18
Dysfunction and ceRNA network of the tumor suppressor miR-637 in cancer development and prognosis	18
Current challenges and best practices for cell-free long RNA biomarker discovery	18
Detection and clinical significance of circulating tumor cells in colorectal cancer	17
Current and emerging therapies for primary central nervous system lymphoma	17
Inhibition of BCL11B induces downregulation of PTK7 and results in growth retardation and apoptosis in T-cell acute lymphoblastic leukemia	17
The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age	17
Epigenetic based synthetic lethal strategies in human cancers	17
Redox signaling and Alzheimer’s disease: from pathomechanism insights to biomarker discovery and therapy strategy	17
Research and application of single-cell sequencing in tumor heterogeneity and drug resistance of circulating tumor cells	17
The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies	16
Engineering T cells with hypoxia-inducible chimeric antigen receptor (HiCAR) for selective tumor killing	16
MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions	15
Sintilimab for the treatment of non-small cell lung cancer	15
HMGA1 augments palbociclib efficacy via PI3K/mTOR signaling in intrahepatic cholangiocarcinoma	15
The REASON score: an epigenetic and clinicopathologic score to predict risk of poor survival in patients with early stage oral squamous cell carcinoma	15
Strategies to enhance CAR-T persistence	15
Extrachromosomal circular DNA (eccDNA): an emerging star in cancer	15
Integration of tumor inflammation, cell proliferation, and traditional biomarkers improves prediction of immunotherapy resistance and response	14
CAR-T cell potency: from structural elements to vector backbone components	14
MicroRNAs as the critical regulators of cell migration and invasion in thyroid cancer	14
The landscape overview of CD47-based immunotherapy for hematological malignancies	14
A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer	14
Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma	14
KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumors	13
Multifaced roles of PLAC8 in cancer	13
Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives	13
Overexpressed immunoglobulin-like transcript (ILT) 4 in lung adenocarcinoma is correlated with immunosuppressive T cell subset infiltration and poor patient outcomes	13
Biomarkers and cell-based models to predict the outcome of neoadjuvant therapy for rectal cancer patients	12
The role of pyroptosis in modulating the tumor immune microenvironment	12
Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma	12
Emerging treatment modalities for systemic therapy in hepatocellular carcinoma	11
The biology of YAP in programmed cell death	11
Empiric use of anticoagulation in hospitalized patients with COVID-19: a propensity score-matched study of risks and benefits	11
Plasma contact factors as novel biomarkers for diagnosing Alzheimer’s disease	11
LncRNAs serve as novel biomarkers for diagnosis and prognosis of childhood ALL	11
Oncolytic viruses for triple negative breast cancer and beyond	11
Advances of mRNA vaccine in tumor: a maze of opportunities and challenges	11
The role of exosomes in tumour immunity under radiotherapy: eliciting abscopal effects?	11
Effect of regulatory cell death on the occurrence and development of head and neck squamous cell carcinoma	11
Functions of RNA N6-methyladenosine modification in acute myeloid leukemia	11
Minimal residual disease in multiple myeloma: current status	11
The lncRNA TEX41 is upregulated in pediatric B-Cells Acute Lymphoblastic Leukemia and it is necessary for leukemic cell growth	10
TBL1XR1 mutation predicts poor outcome in primary testicular diffuse large B-cell lymphoma patients	10
MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study	10
Cervical cancer heterogeneity: a constant battle against viruses and drugs	10
Circulating long non-coding RNA GAS5 (growth arrest-specific transcript 5) as a complement marker for the detection of malignant mesothelioma using liquid biopsies	10
MiR-124-3p impedes the metastasis of non-small cell lung cancer via extracellular exosome transport and intracellular PI3K/AKT signaling	10
Expression and clinical prognostic value of m6A RNA methylation modification in breast cancer	10
Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia	10
PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo	10
A DNA methylation-based test for esophageal cancer detection	10
Direct and indirect effects of IFN-α2b in malignancy treatment: not only an archer but also an arrow	9
Functions and mechanisms of lncRNA MALAT1 in cancer chemotherapy resistance	9
Modulation of the TGF-β signaling pathway by long noncoding RNA in hepatocellular carcinoma	9
Small biomarkers with massive impacts: PI3K/AKT/mTOR signalling and microRNA crosstalk regulate nasopharyngeal carcinoma	9
Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma	9
Targeting serine-glycine-one-carbon metabolism as a vulnerability in cancers	9
The emerging landscape of exosomal CircRNAs in solid cancers and hematological malignancies	9
Galectins and galectin-mediated autophagy regulation: new insights into targeted cancer therapy	9
FAM83A is a potential biomarker for breast cancer initiation	9
Tumor reversion: a dream or a reality	9
Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients	9
Cancer metabolites: promising biomarkers for cancer liquid biopsy	9

The contribution of single-cell analysis of acute leukemia in the therapeutic strategy	9
Donor T cells for CAR T cell therapy	9
Successful treatment of acute B lymphoblastic leukemia relapse in the skin and testicle by anti-CD19 CAR-T with IL-6 knocking down: a case report	8
Lower BCL11B expression is associated with adverse clinical outcome for patients with myelodysplastic syndrome	8
FibroBox: a novel noninvasive tool for predicting significant liver fibrosis and cirrhosis in HBV infected patients	8
circCYP24A1 promotes Docetaxel resistance in prostate Cancer by Upregulating ALDH1A3	8
Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies	8
Assessment of serum macrophage migration inhibitory factor (MIF), adiponectin, and other adipokines as potential markers of proteinuria and renal dysfunction in lupus nephritis: a cross-sectional stud	8
Selective isolation of extracellular vesicles from minimally processed human plasma as a translational strategy for liquid biopsies	8
Oncofetal protein IGF2BPs in human cancer: functions, mechanisms and therapeutic potential	8
Roles and mechanisms of tumour-infiltrating B cells in human cancer: a new force in immunotherapy	8
Bioinformatics tools and data resources for assay development of fluid protein biomarkers	8
SMAD1 as a biomarker and potential therapeutic target in drug-resistant multiple myeloma	8
Molecular mechanisms and clinical applications of exosomes in prostate cancer	8
An analysis of the role of HnRNP C dysregulation in cancers	8
Current advances and future perspectives on the functional roles and clinical implications of circular RNAs in esophageal squamous cell carcinoma: more influential than expected	8
Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives	7
Imaging biomarkers for clinical applications in neuro-oncology: current status and future perspectives	7
Pathophysiological roles of myristoylated alanine-rich C-kinase substrate (MARCKS) in hematological malignancies	7
Circulating MicroRNAs predict glycemic improvement and response to a behavioral intervention	7
ZG16 promotes T-cell mediated immunity through direct binding to PD-L1 in colon cancer	7
Key regulators of sensitivity to immunomodulatory drugs in cancer treatment	7
Emerging agents and regimens for polycythemia vera and essential thrombocythemia	7
Circular RNA circEMB promotes osteosarcoma progression and metastasis by sponging miR-3184-5p and regulating EGFR expression	7
Advances in technology and applications of nanoimmunotherapy for cancer	7
Integrated multiomic approach for identification of novel immunotherapeutic targets in AML	7
Brush swab as a noninvasive surrogate for tissue biopsies in epigenomic profiling of oral cancer	7
Lysyl oxidase expression is associated with inferior outcome and Extramedullary disease of acute myeloid leukemia	7
Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 tr	7
METTL1 promotes neuroblastoma development through m7G tRNA modification and selective oncogenic gene translation	7
A genetic predictive model for precision treatment of diffuse large B-cell lymphoma with early progression	7
Deubiquitinases in hematological malignancies	7
Secondary donor-derived humanized CD19-modified CAR-T cells induce remission in relapsed/refractory mixed phenotype acute leukemia after allogeneic hematopoietic stem cell transplantation: a case repo	7
New cell sources for CAR-based immunotherapy	7
Application and prospects of single cell sequencing in tumors	6
HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives	6
The role and metabolic adaptations of neutrophils in premetastatic niches	6
Long interspersed nuclear element 1 hypomethylation has novel prognostic value and potential utility in liquid biopsy for oral cavity cancer	6
The Wnt/β-catenin signalling pathway in Haematological Neoplasms	6
The role of YAP1 in liver cancer stem cells: proven and potential mechanisms	6
High expression of TMEM244 is associated with poor overall survival of patients with T-cell lymphoma	6
Correction to: LncRNA APCDD1L-AS1 induces icotinib resistance by inhibition of EGFR autophagic degradation via the miR-1322/miR-1972/ miR-324-3p-SIRT5 axis in lung adenocarcinoma	6
Biomarkers as targets for CAR-T/NK cell therapy in AML	6
Leukemia cutis with IDH1, DNMT3A and NRAS mutations conferring resistance to venetoclax plus 5-azacytidine in refractory AML	6
Expression of p52, a non-canonical NF-kappaB transcription factor, is associated with poor ovarian cancer prognosis	6
Targeted proteomics-derived biomarker profile develops a multi-protein classifier in liquid biopsies for early detection of esophageal squamous cell carcinoma from a population-based case-control stud	6
EIF4A3-induced Circ_0001187 facilitates AML suppression through promoting ubiquitin-proteasomal degradation of METTL3 and decreasing m6A modification level mediated by miR-499a-5p/RNF113A pathway	6
Application of double-negative T cells in haematological malignancies: recent progress and future directions	6